NVO - BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies | Benzinga
Clinical-stage biotech innovator BioRestorative Therapies (NASDAQ:BRTX) recently announced that it is entering a new program of preclinical metabolic testing for its patented stem cell biology technology, ThermoStem®.
BioRestorative, which went public in November 2021, is currently engaged in the development of treatments for disc/spine disease and metabolic disorders. In May, the company announced that it would begin a new preclinical metabolic program focused on the treatment of obesity.
Preclinical metabolic programs are detailed studies that examine the safety and efficacy of treatments and are conducted prior to the start of first-in-human (FIH) studies. The company sees significant opportunities for ThermoStem® to help treat the worldwide obesity epidemic.
Morgan Stanley Research estimates that the global market for obesity drugs will be greater than $100 billion by 2030.
"We believe that our proprietary ThermoStem® technology platform has immense potential to develop both best-in-class and first-in-class therapies to treat metabolic disorders such as obesity," said Lance Alstodt, BioRestorative's Chief Executive Officer, when announcing the commencement of the new program.
How ThermoStem® May Be Used To Treat Obesity
Brown adipose tissue (BAT) is a type of body fat that regulates temperature. Our bodies use it to convert food energy into heat. As such, BAT is also a primary target in obesity prevention strategies.
Initial preclinical research indicates that ...